Kintara Therapeutics, Inc.

KTRA | $0.1204 12.95% 11.46% 7.1M

(0.0% 1d) (11.0% 1m) (-97.0% 1y) (0.0% 2d) (0.0% 3d) (-9.2% 7d) (-31.73% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 4,700,163
http://www.kintara.com
Sec Filling | Patents | 19 employees

(US) Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

cancer

add to watch list Paper trade email alert is off

Press-releases

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
Published: 2024-04-10 (Crawled : 01:00) - prnewswire.com
SWAV | $329.02 0.46% 0.46% 1.3M

Health Technology

| 0.05% | O: -0.32% H: 1.09% C: 1.02%
KTRA | $0.1204 12.95% 11.46% 7.1M

Distribution Services

| -25.04% | O: -2.17% H: 0.15% C: -1.69%
ABIO | $3.4 4.61% 4.41% 920K

Health Technology

| 4.22% | O: 1.62% H: 1.92% C: 0.32%

Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm
Published: 2024-04-05 (Crawled : 18:00) - prnewswire.com
SUN | $55.5 2.08% 0.7% 420K

Distribution Services

| -8.46% | O: 0.0% H: 0.14% C: -1.49%
NS | $22.11 2.13% 0.0% 560K

Distribution Services

| -6.45% | O: -0.44% H: 0.96% C: -0.09%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -6.72% | O: -1.84% H: 0.0% C: 0.0%
SWAV | $329.02 0.46% 0.46% 1.3M

Health Technology

| 1.83% | O: 1.21% H: 0.65% C: 0.25%
KTRA | $0.1204 12.95% 11.46% 7.1M

Distribution Services

| -30.41% | O: -13.08% H: 8.09% C: 4.16%
ABIO | $3.4 4.61% 4.41% 920K

Health Technology

| 4.22% | O: -3.9% H: 7.09% C: 4.39%

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Published: 2024-04-03 (Crawled : 11:00) - prnewswire.com
KTRA | $0.1204 12.95% 11.46% 7.1M

Distribution Services

| -0.4% | O: 114.64% H: 11.37% C: -23.9%
therapeutics agreement

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
Published: 2024-02-14 (Crawled : 00:00) - biospace.com/
KTRA | $0.1204 12.95% 11.46% 7.1M

Distribution Services

| -12.36% | O: -1.84% H: 2.68% C: -2.23%
update therapeutics financial results

Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
Published: 2024-02-12 (Crawled : 14:00) - prnewswire.com
KTRA | $0.1204 12.95% 11.46% 7.1M

Distribution Services

| -19.68% | O: 10.84% H: 0.58% C: -14.49%
rem-001 breast cancer treatment trial therapeutics

Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
Published: 2023-12-05 (Crawled : 14:30) - biospace.com/
KTRA | $0.1204 12.95% 11.46% 7.1M

Distribution Services

| -68.65% | O: 6.58% H: 0.0% C: -16.18%
nasdaq granted extension therapeutics

Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study
Published: 2023-10-31 (Crawled : 17:00) - biospace.com/
KTRA | $0.1204 12.95% 11.46% 7.1M

Distribution Services

| -97.34% | O: -73.67% H: 12.12% C: -22.83%
topline therapeutics results study

Agriculture & Natural Solutions SPAC Files for $300M IPO – MarketWatch
Published: 2023-10-24 (Crawled : 22:00) - spacfeed.com
KTRA | $0.1204 12.95% 11.46% 7.1M

Distribution Services